Group 1 - The core point of the article is that Juzhi Biotechnology has been actively repurchasing its shares on the Hong Kong Stock Exchange, indicating a strategy to support its stock price and enhance shareholder value [2] - On December 19, the company repurchased 400,000 shares at a price range of HKD 34.540 to HKD 35.520, with a total repurchase amount of HKD 14.0536 million [2] - Since December 9, the company has conducted share repurchases for nine consecutive days, totaling 3.6 million shares and a cumulative repurchase amount of HKD 127 million [2] Group 2 - The stock price on the day of the repurchase closed at HKD 35.480, reflecting a 2.60% increase, with a total trading volume of HKD 277 million [2] - The detailed repurchase data shows consistent repurchase activity, with each day involving the repurchase of 40,000 shares at varying prices, indicating a structured approach to share buybacks [2] - The cumulative stock price decline during the repurchase period was 2.53%, suggesting that the company's buyback strategy may be aimed at countering this downward trend [2]

巨子生物(02367)发布公告，该公司于2025年12月19日斥资1405.36万港元回购40万股股份，每股回购价 格为34.54-35.52港元。 ...

格隆汇12月19日丨巨子生物(02367.HK)公告，12月19日耗资1405.4万港元回购40万股。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 巨子生物控股有限公司 | 1). | 購回股份擬註銷但尚未註銷 | | 400,000 | 0.0374 % | HKD | 35.941 | | --- | --- | --- | --- | --- | --- | --- | | | 變動日期 | 2025年12月9日 | | | | | | 2). | 購回股份擬註銷但尚未註銷 | | 400,000 | 0.0374 % | HKD | 35.956 | | | 變動日期 | 2025年12月10日 | | | | | | 3). | 購回股份擬註銷但尚未註銷 | | 400,000 | 0.0374 % | HKD | 34.7189 | | | 變動日期 | 2025年12月11日 | | | | | | 4). | 購回股份擬註銷但尚未註銷 | | 400,000 | 0.0374 % | HKD | 35.0909 | | | 變動日期 | 2025年12月12日 | | | | | | 5 ...

Group 1 - The article reports on share buybacks conducted by various companies on December 18, 2025, with Tencent Holdings leading in both the number of shares repurchased and the total amount spent [1] - Tencent Holdings repurchased 1.055 million shares for a total of 636 million yuan, representing 1.030% of its total share capital for the year [2] - Other notable companies involved in the buyback include Xiaomi Group, which repurchased 3.75 million shares for 151 million yuan, and China National Petroleum Corporation, which repurchased 254,000 shares for 116.38 million yuan [3] Group 2 - The total number of shares repurchased by companies varied significantly, with China National Petroleum Corporation having a cumulative buyback of 230 million shares, which is 0.190% of its total share capital [3] - Companies like IGG and VITASOY also participated, with IGG repurchasing 182,000 shares for 68.49 million yuan and VITASOY repurchasing 122,000 shares for 77.94 million yuan [3] - The buyback activity reflects a strategic move by these companies to enhance shareholder value and manage their capital structure effectively [1][2]

12月18日港股公司回购一览 | 代码 | 简称 | 回购股数 | 回购金额（万 | 回购最高价 | 回购最低价 | 年内累计回购金额 | | --- | --- | --- | --- | --- | --- | --- | | | | （万股） | 港元） | （港元） | （港元） | （万港元） | | 00700 | 腾讯控股 | 105.50 | 63564.70 | 605.500 | 599.500 | 7558671.47 | | 01810 | 小米集团-W | 375.00 | 15066.09 | 40.240 | 40.120 | 538831.93 | | 01919 | 中远海控 | 590.00 | 8055.74 | 13.760 | 13.520 | 661473.90 | | 01024 | 快手-W | 123.50 | 8021.93 | 65.600 | 64.350 | 276412.50 | | 00175 | 吉利汽车 | 190.80 | 3179.71 | 16.800 | 16.260 | 29443.33 | | 06098 | 碧桂园服务 | 270 ...

Core Insights - The collagen market is experiencing significant changes with new product approvals from Chongshan Bio and Aibai Rui, expanding the range of certified products in the industry [1][3] - The competition in the animal-derived collagen segment is intensifying, with companies focusing on differentiation through high concentration and specific indications [3] - The recombinant collagen sector is expected to outpace animal-derived collagen in growth, driven by safety and scalability advantages [6][9] Group 1: Product Approvals and Market Dynamics - Chongshan Bio's new product is the world's first implant with a concentration of 45mg/ml, aiming to establish a competitive edge through high concentration [3] - Aibai Rui's product targets specific needs for improving facial smoothness, attempting to create a niche in the crowded market [3] - The number of certified collagen products in China has increased to 14, indicating a growing market but also heightened competition [8] Group 2: Competitive Landscape - The animal-derived collagen market has formed an "eight strong" competitive landscape, with established players like Shuangmei Bio leading due to their early market entry and established clinical safety [3] - New entrants are seeking differentiation through quality ingredients and innovative product forms, such as Fiman Bio's focus on safety and convenience [3][9] - The recombinant collagen market is projected to grow at a compound annual growth rate (CAGR) of 41.4% from 2023 to 2027, compared to 27.7% for animal-derived collagen [6] Group 3: Industry Trends and Future Outlook - The rise of recombinant collagen is attributed to its technological advantages, which mitigate risks associated with animal-derived products [6] - Companies are increasingly focusing on upstream raw material preparation and core production technologies to enhance product quality and safety [9] - The market is expected to see a surge in collagen product offerings in the next two years, as more companies enter the recombinant collagen space [8][9]

Core Viewpoint - The company, Giant Bio, has been actively repurchasing its shares on the Hong Kong Stock Exchange, indicating a strategy to support its stock price amid recent declines [1] Share Buyback Summary - On December 18, 2025, the company repurchased 400,000 shares at a price range of HKD 34.420 to HKD 35.040, totaling HKD 13.883 million [1] - The stock closed at HKD 34.580 on the same day, reflecting a decrease of 1.48%, with a total trading volume of HKD 179 million [1] - Since December 9, 2025, the company has conducted share buybacks for eight consecutive days, acquiring a total of 3.2 million shares for a cumulative amount of HKD 112 million [1] - During this buyback period, the stock has experienced a total decline of 5.00% [1] Buyback Details - The detailed buyback activities are as follows: - December 18: 40,000 shares at a maximum price of HKD 35.040 and a minimum price of HKD 34.420, amounting to HKD 1.3883 million [1] - December 17: 40,000 shares at a maximum price of HKD 35.220 and a minimum price of HKD 34.620, amounting to HKD 1.3971 million [1] - December 16: 40,000 shares at a maximum price of HKD 35.400 and a minimum price of HKD 34.680, amounting to HKD 1.4026 million [1] - December 15: 40,000 shares at a maximum price of HKD 35.240 and a minimum price of HKD 34.440, amounting to HKD 1.3917 million [1] - December 12: 40,000 shares at a maximum price of HKD 35.220 and a minimum price of HKD 35.000, amounting to HKD 1.4036 million [1] - December 11: 40,000 shares at a maximum price of HKD 35.360 and a minimum price of HKD 34.200, amounting to HKD 1.3888 million [1] - December 10: 40,000 shares at a maximum price of HKD 36.220 and a minimum price of HKD 35.620, amounting to HKD 1.4382 million [1] - December 9: 40,000 shares at a maximum price of HKD 36.180 and a minimum price of HKD 35.720, amounting to HKD 1.4376 million [1]

格隆汇12月18日丨巨子生物(02367.HK)公告，12月18日耗资1388.3万港元回购40万股。 ...

Group 1 - The company, 巨子生物 (02367), announced a share buyback plan on December 18, 2025, involving an expenditure of HKD 13.883 million to repurchase 400,000 shares [1]